The value of MRD in transplant-ineligible patients with multiple myeloma

The value of MRD in transplant-ineligible patients with multiple myeloma

April 12, 2024 Meeting of the Oncologic Drugs Advisory Committee (ODAC)Подробнее

April 12, 2024 Meeting of the Oncologic Drugs Advisory Committee (ODAC)

The Evolution of Systemic Therapy for Newly Diagnosed Multiple Myeloma, Dana-Farber Cancer InstituteПодробнее

The Evolution of Systemic Therapy for Newly Diagnosed Multiple Myeloma, Dana-Farber Cancer Institute

Future Directions for Novel and Next Generation Therapy in Multiple Myeloma | Dana-FarberПодробнее

Future Directions for Novel and Next Generation Therapy in Multiple Myeloma | Dana-Farber

Multiple Myeloma: A Pathway to Better OutcomesПодробнее

Multiple Myeloma: A Pathway to Better Outcomes

The prognostic value of MRD negativityПодробнее

The prognostic value of MRD negativity

Prognostic importance of MRD: results of TOURMALINE-MM4 trial for NDMMПодробнее

Prognostic importance of MRD: results of TOURMALINE-MM4 trial for NDMM